Supernus Pharmaceuticals Reports First Quarter 2013 Financial Results
"Oxtellar XRTM continues to impress us with its clinical performance in the market. Prescribers are highly satisfied with the product and patients appreciate its key benefits. We are starting to see meaningful growth in the prescriber base and monthly prescriptions as we head into the middle of the second quarter. We also remain excited about our preparations for the upcoming launch of Trokendi XRTM in the third quarter of this year, pending final
First Quarter 2013 Financial Results
Cash, cash equivalents and marketable securities were
$69.9 millionat March 31, 2013, as compared to $88.5 millionat December 31, 2012.
Research and development expense for the first quarter declined from
$5.4 millionin 2012 to $4.5 millionin 2013, primarily because our Phase IIb study for SPN-810 was completed in 2012.
Selling, general and administrative expense for the first quarter increased from
$2.7 millionin 2012 to $13.5 millionin 2013, reflecting the costs associated with hiring of our 75 rep sales force during the first quarter of 2013, launching Oxtellar XRTM and the prelaunch activities for Trokendi XRTM.
Net deferred product revenue as of
March 31, 2013was $3.6 million. This amount represents shipments to wholesalers during the first quarter of 2013, net of expected wholesaler fees, discounts, and product costs.
Net loss applicable to common shareholders for first quarter 2013 was
$18.4 millionor $0.60per common share (based on 30.9 million weighted average diluted shares outstanding), compared to a net loss of $10.1 millionin the first quarter of 2012 or $6.05per common share (based on 1.7 million weighted average diluted shares outstanding).
Liquidity and Capital Resources
Cash, cash equivalents and marketable securities were
Oxtellar XRTM Launch Update
- We continue to execute well on the launch of Oxtellar XRTM. We are starting to see positive trends in the number of target physicians prescribing the product and the conversion market share, or the percent of the addressable immediate release oxcarbazepine prescriptions that have been converted to Oxtellar XR.
Prescriptions as reported by Symphony/WK for Oxtellar XR in the first two months of its launch totaled 579. We started the second quarter with a healthy momentum, increasing prescriptions to 682 for the four weeks ending
April 26, 2013representing a 58% increase over prescriptions for March 2013.
Based on Symphony/WK data for the week ending
May 3, Oxtellar XR achieved a national conversion market share of the addressable oxcarbazepine prescriptions of 0.58%. For the week ending April 26, among the top group of prescribers where our sales force has been concentrating its efforts, the conversion share is 0.73%. In addition, for the same week, the conversion market share of Oxtellar XR is approximately 2% among the target physicians that have been called on six or more times since launch.
- Comparing the early stage performance of Oxtellar XR to other extended release anti-epileptic products that have been launched, Oxtellar XR seems to be tracking in line with the weekly market share trends of Carbatrol. As a reference, Carbatrol achieved a 1.8% market share of the carbamazepine market in its first 12 months on the market increasing to 4.7% in the second full year after launch. It is premature with few data points to project whether Oxtellar XR will continue to track the share conversion performance of Carbatrol or to use this for revenue guidance.
To date, Oxtellar XR has achieved strong coverage in managed care with 135 million lives covered, 127 million on the commercial side and 8 million on
March 2013at the American Academy of Neurologymeeting, we released data from 214 patients who stayed on Oxtellar XR for 12 months post completion of the blinded portion of our Phase III study. The data shows increased efficacy with seizure frequency reduction up to 59% and further improvement in the adverse event profile leading to AE- related discontinuations of only 5% of patients.
- In summary, we continue to be encouraged with the early signs of the launch primarily because of the following three metrics. First, we believe that one of the most important metrics for a successful launch is satisfaction with the product. We are seeing high levels of satisfaction that prescribing physicians and patients are reporting with Oxtellar XR, consistent with the experience during the 12 months open label study. Second, we have been able to achieve more than 2% conversion share with physicians who have been called on more than six times since the launch. Finally, our sales force continues to build our call frequency.
Regarding Trokendi XR, we continue to expect final approval and commercial launch of Trokendi XR in the third quarter of 2013. The
Finally, regarding the rest of the pipeline we continue to progress SPN 810 with the goal of having a meeting with the
2013 Financial Guidance
In order to support both product launches and the continued development of our pipeline, we project cash burn for 2013 to range from
Assuming availability of data on rebates and allowances, we believe that we will be able to report revenue for Oxtellar XRTM prescriptions which are sold in the first quarter in our quarterly report on Form 10-Q for the quarter ended
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements do not convey historical information, but relate to predicted or potential future events that are based upon management's current expectations. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. In addition to the factors mentioned in this press release, such risks and uncertainties include, but are not limited to, the Company's ability to achieve profitability; the Company's ability to raise sufficient capital to implement its corporate strategy; the implementation of the Company's corporate strategy; the Company's future financial performance and projected expenditures; the Company's ability to enter into future collaborations with
pharmaceutical companies and academic institutions or to obtain funding from government agencies; the Company's product research and development activities, including the timing and progress of the Company's clinical trials, and projected expenditures; the Company's ability to receive, and the timing of any receipt of, regulatory approvals to develop and commercialize the Company's product candidates; the Company's respective PDUFA dates for product candidates and anticipated launch dates for its tentatively approved product; the Company's ability to protect its intellectual property and operate its business without infringing upon the intellectual property rights of others; the Company's expectations regarding federal, state and foreign regulatory requirements; the therapeutic benefits, effectiveness and safety of the Company's product candidates; the accuracy of the Company's estimates
of the size and characteristics of the markets that may be addressed by its product candidates; the Company's ability to increase its manufacturing capabilities for its products and product candidates; the Company's projected markets and growth in markets; the Company's product formulations and patient needs and potential funding sources; the Company's staffing needs; and other risk factors set forth from time to time in the Company's
|CONDENSED CONSOLIDATED BALANCE SHEETS|
|Cash, cash equivalents and marketable securities||
|Other current assets||1,677||1,802|
|Total current assets||76,332||91,462|
|Property and equipment, net||1,687||1,421|
|Deferred financing costs||53||89|
|Other long-term assets||989||1,017|
|Accounts payable and accrued expenses||
|Secured notes payable, current||12,137||11,809|
|Deferred licensing revenue||417||508|
|Deferred product revenue, net||3,551||--|
|Total current liabilities||27,008||22,983|
|Secured notes payable, long-term||7,975||11,088|
|Total Stockholders' Equity||41,272||57,570|
|Total Liabilities & Stockholders Equity||
|Consolidated Statements of Operations|
|(in thousands, except share and per share data)|
Three months ended
|Costs and expenses|
|Research and development||4,522||5,358|
|Selling, general and administrative||13,533||2,728|
|Total costs and expenses||18,055||8,086|
|Other income (expense):|
|Other income (expense)||169||(456)|
|Total other income (expense)||(506)||(1,399)|
|Cumulative dividends on Series A convertible preferred stock||--||(858)|
|Net loss attributable to common stockholders||
|Loss per common share:|
|Basic and diluted||
|Weighted-average number of common shares:|
|Basic and diluted||30,875,424||1,676,442|
Jack Khattar, President and CEO Gregory S. Patrick, Vice President and CFO Supernus Pharmaceuticals, Inc.Tel: (301) 838-2591
News Provided by Acquire Media